Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF). This evidence concerns the gene SLC5A2 and hydrops fetalis.